Singapore markets closed

Repare Therapeutics Inc. (RPTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.93+0.22 (+2.53%)
At close: 04:00PM EDT
8.93 0.00 (0.00%)
After hours: 04:00PM EDT

Repare Therapeutics Inc.

7210 Frederick-Banting
Suite 100
Montreal, QC H4S 2A1
Canada

https://www.reparerx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees158

Key executives

NameTitlePayExercisedYear born
Mr. Lloyd Mitchell SegalPres, CEO & Director913.37k148.07k1964
Mr. Steve ForteExec. VP & CFO608.52kN/A1979
Dr. Michael Zinda Ph.D.Exec. VP & Chief Scientific Officer655.28k1.07M1971
Dr. Maria Koehler M.D., Ph.D.Exec. VP & Chief Medical Officer669.83k892.97k1957
Dr. Daniel Durocher Ph.D.Co-FounderN/AN/AN/A
Dr. Frank Sicheri Ph.D.Co-FounderN/AN/AN/A
Dr. Agnel Sfeir Ph.D.Co-FounderN/AN/AN/A
Dr. Kim A. SethExec. VP and Head of Bus. & Corp. Devel.N/AN/AN/A
Mr. Cameron BlackExec. VP of DiscoveryN/AN/AN/A
Mr. Philip HermanExec. VP of Commercial & New Product Devel.N/AN/A1980
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Corporate governance

Repare Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.